TELESIS BIO (TBIO)
(Delayed Data from NSDQ)
$4.40 USD
+0.23 (5.52%)
Updated Aug 6, 2024 04:00 PM ET
After-Market: $4.32 -0.08 (-1.82%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.40 USD
+0.23 (5.52%)
Updated Aug 6, 2024 04:00 PM ET
After-Market: $4.32 -0.08 (-1.82%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Cronos (CRON) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with its pipeline progress, when Cronos (CRON) reports Q2 results.
Sanofi (SNY) Q2 Earnings Top Estimates, Sales Lag, EPS View Up
by Zacks Equity Research
Sanofi (SNY) beats Q2 estimates for earnings while missing the same for sales. Gain from COVID-19 associated patient stockpiling in the first quarter reverses in this quarter. Stock up.
Cyclacel (CYCC) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Investors will focus on its pipeline progress when Cyclacel (CYCC) reports Q2 results.
Is a Beat in the Cards for Incyte's (INCY) Q2 Earnings?
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Incyte (INCY) reports second-quarter 2020 results.
Akcea (AKCA) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with its pipeline progress, when Akcea (AKCA) reports Q2 results.
What to Expect for Applied Therapeutics (APLT) Q2 Earnings
by Zacks Equity Research
During Applied Therapeutics' (APLT) upcoming Q2 earnings call, investor focus will be on the company's progress with its novel pipeline candidates targeting areas of high unmet medical need.
Is a Beat in Store for Translate Bio (TBIO) in Q2 Earnings?
by Zacks Equity Research
On Translate Bio's (TBIO) Q2 earnings call, investor focus will be on the company's progress with the development of its multiple COVID-19 vaccine candidates in collaboration with Sanofi.
Translate Bio, Inc. (TBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Translate Bio, Inc. (TBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Translate Bio (TBIO) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (TBIO) Outperforming Other Medical Stocks This Year?
The Zacks Analyst Blog Highlights: Alpine Immune Sciences, Actinium Pharmaceuticals, Pacira BioSciences and Translate Bio
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alpine Immune Sciences, Actinium Pharmaceuticals, Pacira BioSciences and Translate Bio
4 Small Drug Stocks Worth Betting on Amid Coronavirus Woes
by Zacks Equity Research
Here we discuss four small stocks from the drug sector, which hold potential for a good run amid the coronavirus crisis.
Sanofi/Regeneron's Kevzara Fails in Phase III Coronavirus Study
by Zacks Equity Research
Sanofi (SNY) and Regeneron discontinue U.S.-based phase III coronavirus study on Kevzara following failure to achieve improvement in hospitalized patients with severe COVID-19 patients of statistical significance.
Heron Therapeutics (HRTX) in Focus: Stock Moves 9% Higher
by Zacks Equity Research
Heron Therapeutics (HRTX) saw a big move last session, as its shares jumped 9% on the day, amid huge volumes.
Spectrum Pharma (SPPI) Soars: Stock Adds 9.2% in Session
by Zacks Equity Research
Spectrum Pharma (SPPI) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Zomedica (ZOM) in Focus: Stock Moves 7.2% Higher
by Zacks Equity Research
Zomedica (ZOM) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Citius Pharmaceuticals (CTXR) Jumps: Stock Rises 5.1%
by Zacks Equity Research
Citius Pharmaceuticals (CTXR) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Are Options Traders Betting on a Big Move in Translate Bio (TBIO) Stock?
by Zacks Equity Research
Investors need to pay close attention to Translate Bio (TBIO) stock based on the movements in the options market lately.
Translate Bio (TBIO) in Focus: Stock Moves 11.7% Higher
by Zacks Equity Research
Translate Bio (TBIO) saw a big move last session, as its shares jumped nearly 12% on the day, amid huge volumes.
Translate Bio Up on Vaccine Agreement Expansion With Sanofi
by Zacks Equity Research
Translate Bio (TBIO) and Sanofi expand their tie-up to develop mRNA vaccines for infectious diseases. The deal boosts the company's cash resources significantly along with potential future revenues.
Company News for Jun 24, 2020
by Zacks Equity Research
Companies In The News Are: SPR, BA, EA, TBIO, SNY, MYOV.
Sanofi Expands Agreement With Translate Bio for mRNA Vaccines
by Zacks Equity Research
Sanofi (SNY) and Translate Bio expand their tie-up to develop mRNA vaccines for infectious diseases. The companies are already developing a mRNA vaccine candidate to combat COVID-19.
Sanofi (SNY) to Create Dedicated Vaccine Center in France
by Zacks Equity Research
Sanofi (SNY) plans to invest almost $690 billion to develop a new production site and research center in France with both dedicated to vaccines.
Will Translate Bio Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor of Translate Bio
Moderna Rallies on Encouraging Coronavirus Vaccine Study Data
by Zacks Equity Research
Moderna's (MRNA) coronavirus vaccine candidate achieves levels of antibodies similar or higher than those typically found in a patient who recovered from COVID-19 naturally.
Translate Bio Inc (TBIO) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Translate Bio Inc (TBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.